2024
EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer
Ermer T, Kim S, Goldberg S, Zolfaghari E, Blasberg J, Boffa D, Herbst R, Politi K, Schalper K, Dacic S, Woodard G. EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s543-s544. DOI: 10.1016/j.jtho.2024.09.1007.Peer-Reviewed Original Research
2023
Alterations in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US
Janczewski L, Cotler J, Merkow R, Palis B, Nelson H, Mullett T, Boffa D. Alterations in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US. JAMA Network Open 2023, 6: e2340148. PMID: 37902756, PMCID: PMC10616721, DOI: 10.1001/jamanetworkopen.2023.40148.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseCancer treatmentAcademic hospitalCommunity hospitalMAIN OUTCOMECOVID-19 pandemicProportion of patientsRetrospective cohort studyAvailability of treatmentFirst yearUnderwent surgeryCohort studyMedian ageCancer surgeryMedian timeTreatment of cancerCancer careTreatment modalitiesCancer screeningCancer DatabaseMedian travel distancePatientsHospitalSurgeryCancerOverall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery
Udelsman B, Canavan M, Zhan P, Ely S, Park H, Boffa D, Mase V. Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. Journal Of Thoracic And Cardiovascular Surgery 2023, 167: 822-833.e7. PMID: 37500052, DOI: 10.1016/j.jtcvs.2023.07.021.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyStage I non-small cell lung cancerLow-comorbidity patientsCell lung cancerOverall survivalSurgical managementLung cancerSurgical resectionBody radiotherapyClinical stage I non-small cell lung cancerEarly-stage non-small cell lung cancerPropensity score-matched cohortPropensity score-matched patientsPropensity score-matched analysisEarly-stage lung cancerLong-term OSNational Cancer DatabaseProportion of patientsCancer DatabasePatientsSBRT patientsSurgeryCancerMortality
2022
Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Johung K, Boffa D. Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer. JTO Clinical And Research Reports 2022, 3: 100429. PMID: 36483656, PMCID: PMC9722471, DOI: 10.1016/j.jtocrr.2022.100429.Peer-Reviewed Original ResearchStage IV esophageal cancerNational Cancer DatabaseEsophageal cancerCancer DatabaseRadiation doseSurvival advantageMedian total radiation dosePropensity score-matched pairsOutcome of radiationRetrospective cohort studyKaplan-Meier analysisTotal radiation doseAppropriate radiation dosePalliative regimensCohort studyMedian ageRadiation administrationSurvival associationsBetter survivalPatientsLocal controlCancerDosePalliationFurther studiesCancer of the Lung
Morgensztern D, Boffa D, Chen A, Dhanasopon A, Goldberg S, Decker R, Devarakonda S, Ko J, Soto L, Waqar S, Wistuba I, Herbst R. Cancer of the Lung. 2022, 1-29. DOI: 10.1002/9781119000822.hfcm085.pub2.Peer-Reviewed Original ResearchOA11.03 Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Non-Small Cell Lung Cancer: A Marker of Better Prognosis
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Boffa D. OA11.03 Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Non-Small Cell Lung Cancer: A Marker of Better Prognosis. Journal Of Thoracic Oncology 2022, 17: s29-s30. DOI: 10.1016/j.jtho.2022.07.056.Peer-Reviewed Original ResearchAssociation of Insurance Status and Extent of Organ Involvement With Survival Among Patients With Stage IV Cancer
Zhan PL, Canavan ME, Ermer T, Pichert MD, Li AX, Maduka RC, Boffa DJ. Association of Insurance Status and Extent of Organ Involvement With Survival Among Patients With Stage IV Cancer. JAMA Network Open 2022, 5: e2217581. PMID: 35713907, PMCID: PMC9206181, DOI: 10.1001/jamanetworkopen.2022.17581.Peer-Reviewed Original ResearchAppendiceal Cancer in the National Cancer Database: Increasing Frequency, Decreasing Age, and Shifting Histology.
Salazar MC, Canavan ME, Chilakamarry S, Boffa DJ, Schuster KM. Appendiceal Cancer in the National Cancer Database: Increasing Frequency, Decreasing Age, and Shifting Histology. Journal Of The American College Of Surgeons 2022, 234: 1082-1089. PMID: 35703801, DOI: 10.1097/xcs.0000000000000172.Peer-Reviewed Original ResearchConceptsRight-sided colon cancerNational Cancer DatabaseAppendiceal cancerColon cancerAcute appendicitisNonoperative managementCancer DatabasePatients 49 yearsPatients 18 yearsArea of residenceLogistic regression modelsAppendiceal histologyPatients 40Appendectomy specimensPatient ageCarcinoid tumorsAppendiceal carcinoidsCancer incidenceCancer histologySmall studyAge groupsCancerCarcinoidsLogistic regressionHistology
2021
Twenty-Five Years of Cancer Follow-Up; Is the Data Worth the Effort?
Brajcich BC, Palis BE, McCabe R, Nogueira L, Boffa DJ, Lum SS, Harris JB, Hawhee V, Mullett TW, Bilimoria KY, Nelson H. Twenty-Five Years of Cancer Follow-Up; Is the Data Worth the Effort? Annals Of Surgical Oncology 2021, 29: 828-836. PMID: 34689251, DOI: 10.1245/s10434-021-10668-w.Peer-Reviewed Original ResearchChange in facility-level share of Medicaid patients with cancer following implementation of the affordable care act.
Buck M, Demkowicz P, Nie J, Marks V, Salazar M, Kenney P, Boffa D, Leapman M. Change in facility-level share of Medicaid patients with cancer following implementation of the affordable care act. Journal Of Clinical Oncology 2021, 39: e18543-e18543. DOI: 10.1200/jco.2021.39.15_suppl.e18543.Peer-Reviewed Original ResearchProportion of MedicaidAffordable Care ActMedicaid patientsMedicaid expansionFacility-level changesFacility-level policiesNational Cancer DatabasePrimary study endpointProportion of patientsInsurance coverageMultivariable logistic regressionExpansion statesCare ActFacility-level factorsMedicaid expansion statesNon-expansion statesAdult patientsStudy endpointAdjusted differenceCancer DatabaseMedicaid populationEligible facilitiesPatientsCancerLogistic regression
2020
COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network
Network I, Antonoff M, Backhus L, Boffa DJ, Broderick SR, Brown LM, Carrott P, Clark JM, Cooke D, David E, Facktor M, Farjah F, Grogan E, Isbell J, Jones DR, Kidane B, Kim AW, Keshavjee S, Krantz S, Lui N, Martin L, Meguid RA, Meyerson SL, Mullett T, Nelson H, Odell DD, Phillips JD, Puri V, Rusch V, Shulman L, Varghese TK, Wakeam E, Wood DE. COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. Journal Of Thoracic And Cardiovascular Surgery 2020, 160: 601-605. PMID: 32689703, PMCID: PMC7146695, DOI: 10.1016/j.jtcvs.2020.03.061.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusClinical Decision-MakingConsensusCoronavirus InfectionsCOVID-19Delivery of Health Care, IntegratedHealth Services Needs and DemandHost Microbial InteractionsHumansNeeds AssessmentOccupational HealthPandemicsPatient SafetyPatient SelectionPneumonia, ViralRisk AssessmentRisk FactorsSARS-CoV-2Thoracic NeoplasmsThoracic Surgical ProceduresTime-to-TreatmentTriageCOVID-19 Guidance for Triage of Operations for Thoracic Malignancies: A Consensus Statement From Thoracic Surgery Outcomes Research Network
Network I, Antonoff M, Backhus L, Boffa D, Broderick S, Brown L, Carrott P, Clark J, Cooke D, David E, Facktor M, Farjah F, Grogan E, Isbell J, Jones D, Kidane B, Kim A, Keshavjee S, Krantz S, Lui N, Martin L, Meguid R, Meyerson S, Mullett T, Nelson H, Odell D, Phillips J, Puri V, Rusch V, Shulman L, Varghese T, Wakeam E, Wood D. COVID-19 Guidance for Triage of Operations for Thoracic Malignancies: A Consensus Statement From Thoracic Surgery Outcomes Research Network. The Annals Of Thoracic Surgery 2020, 110: 692-696. PMID: 32278755, PMCID: PMC7146713, DOI: 10.1016/j.athoracsur.2020.03.005.Peer-Reviewed Original ResearchSurgeon's Perspective to Local Therapy in Oligometastatic Cancer.
Boffa DJ. Surgeon's Perspective to Local Therapy in Oligometastatic Cancer. The Cancer Journal 2020, 26: 149-155. PMID: 32205540, DOI: 10.1097/ppo.0000000000000441.Peer-Reviewed Original Research
2018
Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
Goodman K, Hall N, Bekaii-Saab T, Ou F, Twohy E, Meyers M, Boffa D, Mitchell K, Perry K, Frankel W, Venook A, O'Reilly E, Ilson D. Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. Journal Of Clinical Oncology 2018, 36: 4012-4012. DOI: 10.1200/jco.2018.36.15_suppl.4012.Peer-Reviewed Original Research
2017
Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, Boffa DJ, Kim AW. Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians. Surgery 2017, 162: 640-651. PMID: 28697883, DOI: 10.1016/j.surg.2017.04.025.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overCarcinoma, Non-Small-Cell LungConfidence IntervalsDatabases, FactualDisease-Free SurvivalFemaleGeriatric AssessmentHumansKaplan-Meier EstimateLogistic ModelsLung NeoplasmsMaleMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingOdds RatioPneumonectomyProportional Hazards ModelsRadiotherapyRegistriesRisk AssessmentSecondary PreventionSurvival AnalysisConceptsCell lung cancerLocal therapyLung cancerStage IRelative survivalStereotactic body radiation therapyNational Cancer DatabaseBetter overall survivalBody radiation therapyOlder patientsOverall survivalPatient ageYounger patientsOverall mortalityPrimary outcomeCancer DatabaseTreatment outcomesTreatment decisionsRadiation therapyPatientsTherapyCancerNonagenariansTreatmentSurvivalIndications for Invasive Mediastinal Staging in Patients with Early Non–Small Cell Lung Cancer Staged with Positron Emission Tomography-Computed Tomography
Gao S, Kim A, Puchalski J, Bramley K, Detterbeck F, Boffa D, Decker R. Indications for Invasive Mediastinal Staging in Patients with Early Non–Small Cell Lung Cancer Staged with Positron Emission Tomography-Computed Tomography. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: 223. DOI: 10.1016/j.ijrobp.2017.01.061.Peer-Reviewed Original Research
2016
The Eighth Edition Lung Cancer Stage Classification
Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. CHEST Journal 2016, 151: 193-203. PMID: 27780786, DOI: 10.1016/j.chest.2016.10.010.Peer-Reviewed Original ResearchConceptsLung cancer stage classificationCancer stage classificationCohort of patientsAnatomic extentContemporary patientsLung cancerClinical studiesStage classificationEighth editionSpecific patientPatientsInternal validationCancerStage classification systemMultiple assessmentsClassification systemCohortCliniciansTiming of Surgery After Neoadjuvant Chemoradiation in Clinical Stage IIIA Non-Small Cell Lung Cancer With Mediastinal Nodal Involvement
Gao S, Corso C, Wang E, Blasberg J, Boffa D, Detterbeck F, Kim A. Timing of Surgery After Neoadjuvant Chemoradiation in Clinical Stage IIIA Non-Small Cell Lung Cancer With Mediastinal Nodal Involvement. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e470. DOI: 10.1016/j.ijrobp.2016.06.1811.Peer-Reviewed Original ResearchIndications for Invasive Mediastinal Staging in Patients With Early Non-Small Cell Lung Cancer Staged With Positron Emission Tomography/Computed Tomography
Gao S, Kim A, Detterbeck F, Boffa D, Puchalski J, Decker R. Indications for Invasive Mediastinal Staging in Patients With Early Non-Small Cell Lung Cancer Staged With Positron Emission Tomography/Computed Tomography. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s11. DOI: 10.1016/j.ijrobp.2016.06.041.Peer-Reviewed Original Research75P PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study
Graf R, Lu D, Krupa R, Louw J, Dugan L, Jendrisak A, Orr S, Bethel K, Wang Y, Suraneni M, Landers M, Boffa D, Nieva J, Bazhenova L, Salazar M, Makani S, Magana M, Dittamore R. 75P PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study. Annals Of Oncology 2016, 27: vi22. DOI: 10.1093/annonc/mdw363.23.Peer-Reviewed Original Research